Project Grant HT9425261E176
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded UC San Diego a $1.65 million project grant under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2026, through April 30, 2029. The award supports research focused on targeting oncoembryonic antigens to overcome therapy resistance in patients with triple-negative breast cancer. This research initiative represents a translational oncology effort within the DHA's broader portfolio of...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $993,283 Project Grant to The Regents of the University of California, San Francisco under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2027. The award supports research into the proteomic determinants and components of progression in multiple sclerosis. This research initiative aligns with the DHA's mission to transform healthcare for service members...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $1,197,884 Project Grant to the University of California, San Diego under the Military Medical Research and Development program (CFDA 12.420) for the project titled "Mechanism Dissection and Model Development of Human PD1 in Melanoma." The award was issued on August 15, 2025, with a performance period extending through August 14, 2028. The research will be conducted at UC San Diego's La Jolla, California campus. This...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $999,999 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 28, 2025, through September 27, 2028. The award funds research to uncover the relationship between myelin and synapse dynamics in multiple sclerosis. This three-year initiative supports hypothesis-driven biomedical research designed to advance...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,257,982 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded August 1, 2025, with a completion date of July 31, 2028. The project, titled "Mapping the RNA Splicing Landscape of NF1 and Its Impact on Neurofibromin Function Across Tissues," supports advanced biomedical research focused on understanding RNA...
- Award Summary The University of California, San Diego received a $1,197,813 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the project "Mechanism Dissection and Model Development of Human PD1 in Melanoma." The award, effective August 15, 2025 through August 14, 2028, supports research focused on advancing understanding of PD1 (Programmed Death receptor 1) mechanisms in melanoma as part of DHA's broader...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,226,730 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2029. The award funds research investigating the canonical Polycomb Repressive Complex 1 (cPRC1) as an intrinsic mechanism of resistance to enzalutamide in advanced prostate cancer. This hypothesis-driven research initiative...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $999,999 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2028. This award supports the development and validation of cell-free deoxyribonucleic acid (DNA) epigenetic biomarkers for multiple sclerosis, a three-year research initiative conducted at UCSF's San Francisco facility. The project...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $1.23 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2025, with a completion date of September 29, 2029. The award supports research to validate CD46 as a promising biomarker in advanced prostate cancer, aligning with the DHA's mission to transform healthcare for service members and the...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1.97M Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports the development of CD46-targeted antibody fragment radiopharmaceutical therapy for prostate cancer treatment. This research initiative represents a translational medicine effort to advance diagnostic and...
The University of California, San Diego received a $3.49M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to develop disease-modifying therapies for fibrous dysplasia using a targeted protein degradation approach. The award, effective July 1, 2026, through June 30, 2030, supports basic and applied biomedical research aimed at transforming healthcare for military service members and the American public. The research will be conducted at UCSD's La Jolla, California campus, leveraging the institution's expertise as a research-intensive academic medical center with established capabilities in advanced biomedical research and therapeutic development. This project represents the DHA's commitment to funding hypothesis-driven research that addresses critical health challenges through innovative medical solutions. As a premier research institution with recent federal grant awards exceeding $150M annually across diverse biomedical domains, UCSD is well-positioned to deliver translational research outcomes and advance knowledge in fibrous dysplasia treatment. The four-year performance period aligns with typical DHA project grant structures, which emphasize both technical merit and military relevance through a rigorous two-tier competitive review process.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $3.5m | 5/8/26 |